financetom
Business
financetom
/
Business
/
Indian defence cos see momentum shift as 'aatmanirbhar' theme plays
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indian defence cos see momentum shift as 'aatmanirbhar' theme plays
Apr 5, 2022 4:15 AM

In an interview to CNBC-TV18, Siddharth Mishra, CMD of Bharat Dynamics; JD Patil, whole-time director of defence and smart tech at L&T and defence expert Ajai Shukla discussed the Indian defence sector at length.

First up, Patil said that Indian defence companies with a focus on ‘Aatmanirbhar’ will see good growth going ahead.

He said, “The Indian defence companies with ‘aatmanirbhar’ focus, which the government is shifting dramatically to, we shall see a good amount of growth in terms of opportunities. However, one hassle which always existed was that the government was not spending enough on R&D; it was spending on R&D in the public sector, the government-owned organisation called Defence Research.”

Meanwhile, Mishra said, “Missile technology will remain in force and we are working on short-range missiles and we are working on long-distance surface to surface missiles and these are going to be the future of missile warfare

Bharat Dynamics, said Mishra, is working with Defence Research and Development Organisation (DRDO) to develop its own technology related to defence.

Also Read: India will 'possibly' not import any defence items going forward: Defence Ministry official

Defence expert Ajai Shukla said that several weapon systems have a high degree of indigenization. He also expects to see a sharp shortfall in raw materials related to defence.

For the entire discussion, watch the accompanying video

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
S&P Global Ratings Previews This Week's Bank of Canada Policy Meeting
S&P Global Ratings Previews This Week's Bank of Canada Policy Meeting
Mar 11, 2025
07:35 AM EDT, 03/11/2025 (MT Newswires) -- S&P Global Ratings said it anticipates the Bank of Canada will lower interest rates by 25bps this week, bringing the rate down to 2.75%. This follows a substantial 200bps reduction in overnight rates since the Canadian central bank began its monetary policy normalization last June. The BoC is slated to release its policy...
Tilray Medical Introduces High THC, High Terpene Genetics to German Medical Cannabis Market
Tilray Medical Introduces High THC, High Terpene Genetics to German Medical Cannabis Market
Mar 11, 2025
08:01 AM EDT, 03/11/2025 (MT Newswires) -- Tilray Medical, a division of Tilray Brands ( TLRY ), (TLRY.TO) on Tuesday said it is introducing in Germany the Tilray Craft brand, a new extension of the Tilray Medical brand. Tilray Craft is being introduced to address the needs of patients in Germany for flower-based medical cannabis with higher THC and higher...
BRIEF-Labcorp Announces Acquisition Of Select Assets Of Bioreference Health's Innovative Oncology And Related Clinical Testing Services Businesses
BRIEF-Labcorp Announces Acquisition Of Select Assets Of Bioreference Health's Innovative Oncology And Related Clinical Testing Services Businesses
Mar 11, 2025
March 11 (Reuters) - Labcorp Holdings Inc ( LH ): * LABCORP ANNOUNCES ACQUISITION OF SELECT ASSETS OF BIOREFERENCE HEALTH'S INNOVATIVE ONCOLOGY AND RELATED CLINICAL TESTING SERVICES BUSINESSES * LABCORP ( LH ): PURCHASE PRICE FOR TRANSACTION IS UP TO $225 MILLION Source text: Further company coverage: ...
Top Premarket Decliners
Top Premarket Decliners
Mar 11, 2025
07:58 AM EDT, 03/11/2025 (MT Newswires) -- Zymeworks ( ZYME ) shares slumped 46% pre-bell Tuesday, adding to Monday's losses. Arvinas ( ARVN ) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat...
Copyright 2023-2026 - www.financetom.com All Rights Reserved